John J. Castellani is President and Chief Executive Officer of the Pharmaceutical Research and Manufacturers of America (PhRMA), an organization that represents America’s leading biopharmaceutical research companies.
Living with cancer takes a toll on anyone, but it can be especially devastating for uninsured and low-income patients. That’s why the 340B Drug Pricing Program is such an important issue. Congress created this program in 1992 to help improve access to medical services for this population. The program works by providing discounted prescription drugs to hospitals and clinics that serve high numbers of uninsured, low-income patients.
The Society for Women’s Health Research is the nation’s only nonprofit organization whose mission is to improve the health of all women through research, education and advocacy. We believe that the 340B program is vital to ensuring that indigent women in the United States have access to quality health care and medications. SWHR is concerned that a recent report seriously calls into question whether that mission is being realized.